A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection

Inclusion Criteria: * Renal allograft recipients receiving their first or second allograft * Age over 18 * Maintained on conventional immunosuppression * Completed informed consent document Exclusion Criteria: * Known hypersensitivity to MEDI-507 * More than two renal allografts * Moribund and unlikely (in the opinion of the investigator) to survive the duration of the trial * Simultaneous use of other investigational agents (this does not include the use of licensed agents for indications not listed in the package insert) * Any of the following clinical settings or diagnoses posttransplant: pregnancy or nursing mother: Ø Human Immunodeficiency Virus infection Ø hemodialysis or chronic peritoneal dialysis Ø use of a ventilator Ø hyperacute rejection * Having received OKT3, tacrolimus, or antilymphocyte globulin during the current allograft * Less than 10 ml/hr average urine output over 4 hours since the end of surgery